Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)
10. juni 2015 oppdatert av: AbbVie (prior sponsor, Abbott)
Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice
The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
This was a postmarketing observational study (PMOS) for participants with insufficiently controlled, moderate to severe, active AS who were eligible for adalimumab therapy.
Participants started treatment with adalimumab under normal clinical settings in Germany.
Enrolled participants were followed during adalimumab therapy .
Participants were assessed during regular clinic visits for up to 24 months and 359 clinicians (rheumatologists/orthopedists/general practitioners/internist) participated in the study.
Since this was an observational trial, not all doctors followed the stated age limitations and some participants under the age of 18 were enrolled.
Studietype
Observasjonsmessig
Registrering (Faktiske)
4681
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Participants with AS in routine clinical practice.
Beskrivelse
Inclusion Criteria:
- Participants with active, AS for at least 4 weeks (BASDAI greater than or equal to 4).
- Participants who failed treatment with two non-steroidal anti-inflammatory drugs (NSAIDs).
- No contraindications for anti-tumor necrosis factors (TNF) therapy.
Exclusion Criteria:
1. Participants who do not meet the above listed inclusion criteria.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Bare etui
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Ankylosing spondylitis
Participants with ankylosing spondylitis
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The BASDAI was a six question, participant-reported measure of overall disease activity that probed the level of fatigue, neck/back/hip pain, peripheral joint swelling and pain, localized tenderness, as well as morning stiffness severity and duration.
It was scored on a numerical rating scale that ranged from 0 (no symptoms) to 10 (severe symptoms), and the minimum clinically important difference (MCID) was 1.0.
The final BASDAI score was calculated using the following equation, in which 01 - 06 represents the question number: (BASDAI01 + BASDAI02 + BASDAI03 + BASDAI04 + BASDAI05/2 + BASDAI06*1.25/2)/5.
The scale for question 6 was reduced to 0-8 since BASDAI06 was multiplied by 1.25.
Data are reported as the mean change total score from baseline (Month 0).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The BASFI was a ten question, participant-reported measure that evaluated physical function.
Each question was scored on a numerical rating scale that ranged from 0 (no functional impairment) to 10 (maximal impairment), and the MCID was 0.7.
The mean of the ten questions was the total BASFI score.
Data are reported as the mean change of total score from baseline (Month 0).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Number of Participants With Drug-Related Adverse Events (AEs)
Tidsramme: From signing of informed consent up to 24 months
|
An adverse event/adverse experience was any reaction, side effect or other untoward event associated with the use of a drug in humans, whether or not the event was considered drug related.
This included adverse events occurring from accidental or deliberate drug overdose, from drug abuse, or from drug withdrawal.
Exacerbations of pre-existing conditions are also considered adverse events.
Data presented are adverse events that are drug-related and are detailed in the adverse event section of this report.
|
From signing of informed consent up to 24 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean Number of Involved Peripheral Joints
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Peripheral joints were assessed by Tender Joint Counts (TJC) and Swollen Joint Counts (SJC), using pressure and joint manipulation during physical examination.
Seventy-eight TJC and 76 SJC were evaluated and a score of 0 (not tender or swollen) or 1 (tender or swollen) was assigned for each joint with a higher total score indicating a greater number of involved joints.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants With Extraspinal Manifestations
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Extraspinal manifestations (enthesitis, dactylitis, uveitis, psoriasis, and Inflammatory Bowel Disease (IBD)) were assessed by investigators and reported on the basis of their clinical evaluation and participant records.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Erythrocyte Sedimentation Rate (ESR)
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Plasma concentrations of ESR were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Plasma Concentrations of C-Reactive Protein (CRP)
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Plasma concentrations of CRP were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Bath Ankylosing Spondylitis-Global (BAS-G) Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The BAS-G was a participant-reported instrument with two items.
In the first item, the participant rated the effect of their disease over the last week, and in the second item, the participant rated the effect of their disease over the previous 6 months.
Each item of the BAS-G was scored on a scale ranging from 0 (no effect) to 10 (very severe effect).
The mean of the two scores was the total BAS-G score and the MCID was 1.5.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Global Assessment of Disease Activity Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Global Assessment of Disease Activity was a participant-reported measure that evaluated disease activity.
It was scored on a scale that ranged from 0 to 10; lower scores indicated better patient status.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Participant Fatigue Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Using the BASDAI questionnaire, participants assessed the overall level of fatigue/tiredness experienced by him/her.
It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Participant Pain Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Using the BASDAI questionnaire, participants assessed the overall level of AS neck, back or hip pain experienced by him/her.
It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants With Morning Stiffness
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Morning stiffness was a participant-reported assessment.
The number of participants with morning stiffness were assessed at each visit.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Duration of Morning Stiffness
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Participants accessed the duration of morning stiffness in 15 minute intervals from 0 to 2 hours.
Data are reported as the mean duration of morning stiffness ± standard deviation.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) Improvement Criteria
Tidsramme: At 3, 6, 9, 12, 18, and 24 months
|
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst).
To qualify for a 20% improvement, participants were required to have an improvement of greater than or equal to 20% and greater than or equal to 1 unit in at least 3 domains, and no worsening of greater than or equal to 20% and greater than or equal to 1 unit in the remaining domain.
To achieve a 40% improvement, participants were required to have an improvement of greater than or equal to 40% and greater than or equal to 2 units in at least 3 domains, and no worsening at all in the remaining domain.
|
At 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants Achieving ASAS Partial Remission Criteria
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst).
To qualify for a partial remission, participants had to have values of 2 or less (on a scale of 10) in each of the 4 domains.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants With Impairment in Daily Activities During the Last 4 Weeks
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The impairment of daily activities was based on participant recall of events that occurred over the 4 weeks before the visit.
Percentage of participants with impairment for 0, less than 7, 7 to 14, and greater than 14 days was assessed.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants Who Missed Work Days Due to Ankylosing Spondylitis (AS) in the Previous 12 Months
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Mean Missed Work Days Due to Ankylosing Spondylitis in the Previous 12 Months
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants With In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Mean Days of In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants on Adalimumab Monotherapy
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants With Concomitant Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants With Concomitant Pain Relief/Anti-Inflammatory Agents
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Participants with concomitant pain relief/anti-inflammatory agents like analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, and systemic glucocorticoids were assessed during the study period.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Equivalent Dose of Prednisolone
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The mean equivalent dose of prednisolone was calculated based on the International Standard for comparison of different glucocorticoid products.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Bianca Wittig, MD, AbbVie Deutschland GmbH & Co. KG, Medical Department
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2006
Primær fullføring (Faktiske)
1. mai 2014
Studiet fullført (Faktiske)
1. mai 2014
Datoer for studieregistrering
Først innsendt
1. mars 2010
Først innsendt som oppfylte QC-kriteriene
2. mars 2010
Først lagt ut (Anslag)
3. mars 2010
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
9. juli 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
10. juni 2015
Sist bekreftet
1. juni 2015
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P10-147
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Ankyloserende spondylitt
-
Diakonhjemmet HospitalUniversity of OsloFullførtAnkyloserende spondylitisNorge